Mainz Biomed announces its participation in the American Society of Clinical Oncology, ASCO, 2024 Annual Meeting. This prestigious conference will be held from May 31 to June 4, 2024, in Chicago, Illinois, and online, serving as a leading forum for the latest developments in oncology. The combined analysis from the ColoFuture and eAArly DETECT studies represents the largest dataset to date, with 690 subjects including previously unexamined and unreported subjects enrolled across 30 clinical sites. These studies were designed to assess the performance of a novel stool-based approach that combines mRNA signatures and the Fecal Immunochemical Test with an AI-generated algorithm to improve diagnostic performance for detecting colorectal cancer and advanced precancerous lesions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
- Mainz Biomed unveils key findings from eAArly DETECT study
- Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
- Mainz Biomed to present results of colorectal cancer study at DDW 2024
- Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.